EUVIMEDExplore EUVIMED
Multizentrische StudieBeobachtungsstudieKohortenstudieStudienprotokollOpen access

Real-World Effectiveness and Safety of Liuwei Dihuang Pill for Menopausal Syndrome: Protocol for a Prospective, Observational, Multicenter Cohort Study

Shuoshuo Wei iD, Hongyan Zhang iD, Mengmeng Wang iD, Yuhui Sun iD, Tao Song iD, Weifang Zheng iD, Yunmei Ye iD, Liran Ma iD, Yunshuang Yang iD, Tong Wei iD, Lan Cheng iD, Chunquan Sun iD and 4 more

JMIR Research Protocols · 2026-03-25 · 15 · e84803

DOI: 10.2196/84803 ↗

At a glance

Multizentrische Studie in JMIR Research Protocols, published online on 2026-03-25. Written by Shuoshuo Wei and 15 co-authors. Institution: Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China. Major MEDLINE topics: Drugs, Chinese Herbal, Menopause. Cited 1 times so far (Crossref); 34 references. The full text is freely available in PubMed Central.

AbstractSubjectsBibliographic detailsCiteRelated studies

Abstract (original language)

Background

Menopausal syndrome (MPS) results from declining ovarian function and estrogen fluctuations during the menopausal transition, typically presenting with vasomotor, psychological, and metabolic symptoms that impair quality of life. Current treatments, including hormone replacement therapy and nonhormonal medications, are limited by safety concerns and adverse effects. The Liuwei Dihuang (LWDH) pill, a classical traditional Chinese medicine formula, is widely used for kidney-yin deficiency and menopausal symptoms such as hot flashes, insomnia, depression, and anxiety. Preliminary studies suggest favorable efficacy and safety; however, robust real-world evidence, particularly in combination with conventional Western therapy, remains insufficient.

Objective

This study aims to evaluate the real-world effectiveness and safety of LWDH in combination with conventional Western therapy for MPS.

Methods

This prospective, multicenter, real-world, observational cohort study will be conducted at 8 centers in China from March 9, 2025, to December 2026. A total of 1000 patients with MPS in a real-time clinical setting will be allocated to either the exposure group (conventional therapy plus LWDH) or the nonexposure group (conventional therapy alone). The primary outcome is the change in the modified Kupperman Index. The secondary outcomes encompass changes in the Menopausal Quality of Life Scale, serum sex hormone levels, traditional Chinese medicine syndrome scores, and metabolic parameters. Metabolomics analyses will be conducted to explore potential mechanisms. Safety will be assessed by monitoring adverse events and clinically significant abnormalities in vital signs or laboratory parameters. Assessments will be conducted at baseline and at 2 and 4 weeks, with a subsequent 2-week follow-up. Propensity score–based inverse probability of treatment weighting will be applied to balance baseline covariates, and weighted regression models will be used for comparative analyses.

Results

Participant recruitment and enrollment began in March 2025. It is expected that by December 2026, a total of 1000 participants will be recruited. At present, patient recruitment is ongoing, and preliminary organization and analysis of medical record data are underway. Blood sample collection for metabolomics analysis is also in progress. Final data collection is expected to be completed in March 2027. We expect to generate evidence to support clinical decision-making, with results anticipated to be published in esteemed, peer-reviewed health research journals by December 2027.

Conclusions

This study will assess the clinical effectiveness, safety, and potential mechanisms of LWDH in the treatment of MPS in real-world settings, providing a scientific basis for its use in clinical practice. Trial Registration ClinicalTrials.gov NCT06874738; https://clinicaltrials.gov/study/NCT06874738 International Registered Report Identifier (IRRID) DERR1-10.2196/84803

Subjects

MeSH terms (MEDLINE)

Drugs, Chinese HerbalMenopauseHumansFemaleProspective StudiesChinaSyndromeQuality of LifeTreatment OutcomeMiddle Aged

Author keywords

Liuwei Dihuang pilleffectivenessmenopausal syndromeprotocolreal worldsafety

Substances

Drugs, Chinese HerbalLiuwei Dihuang Decoction

Authors and institutions

  • Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China.
  • First Affiliated Hospital of Harbin Medical University, Heilongjiang, China.
  • Lanxi Hospital of Traditional Chinese Medicine, Zhejiang, China.
  • Beijing Gulou Hospital of Traditional Chinese Medicine, Beijing, China.
  • Beijing Longfu Hospital, Beijing, China.
  • Hepingli Community Health Service Center, Dongcheng District, Beijing, China.

ORCID profiles: Shuoshuo Wei, Hongyan Zhang, Mengmeng Wang, Yuhui Sun, Tao Song, Weifang Zheng, Yunmei Ye, Liran Ma, Yunshuang Yang, Tong Wei, Lan Cheng, Chunquan Sun, Xingting Ding, Shichu Zhao, Qingqiao Song, Lianxin Wang

Cite

APA

Wei, S., Zhang, H., Wang, M., Sun, Y., Song, T., Zheng, W., Ye, Y., Ma, L., Yang, Y., Wei, T., Cheng, L., Sun, C., Ding, X., Zhao, S., Song, Q., & Wang, L. (2026). Real-World Effectiveness and Safety of Liuwei Dihuang Pill for Menopausal Syndrome: Protocol for a Prospective, Observational, Multicenter Cohort Study. JMIR Research Protocols, 15, e84803. https://doi.org/10.2196/84803

Vancouver

Wei S, Zhang H, Wang M, Sun Y, Song T, Zheng W, et al. Real-World Effectiveness and Safety of Liuwei Dihuang Pill for Menopausal Syndrome: Protocol for a Prospective, Observational, Multicenter Cohort Study. JMIR Research Protocols. 2026;15:e84803. doi:10.2196/84803

BibTeX
@article{Wei2026,
  author = {Wei, Shuoshuo and Zhang, Hongyan and Wang, Mengmeng and Sun, Yuhui and Song, Tao and Zheng, Weifang and Ye, Yunmei and Ma, Liran and Yang, Yunshuang and Wei, Tong and Cheng, Lan and Sun, Chunquan and Ding, Xingting and Zhao, Shichu and Song, Qingqiao and Wang, Lianxin},
  title = {Real-World Effectiveness and Safety of Liuwei Dihuang Pill for Menopausal Syndrome: Protocol for a Prospective, Observational, Multicenter Cohort Study},
  journal = {JMIR Research Protocols},
  year = {2026},
  volume = {15},
  pages = {e84803},
  doi = {10.2196/84803}
}
Start for free →